Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

CAMBRIDGE, Mass., Sept. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, 2009 at 10:55 a.m. ET at the Four Seasons Hotel in Boston, Massachusetts, and at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September( )14, 2009 at 3:55 p.m. ET at the Grand Hyatt Hotel, New York.

The live and archived webcasts of the presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the events to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
2. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
3. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
4. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
7. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
8. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
10. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
11. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... provide a,sensitive method to detect protease activity, measure ... of drug candidates. LI-COR,Biosciences now offers three different ... BACE, and IRDye 800CW/QC-1 CSP-3., "These substrates ... conjugated dye by our novel IRDye QC-1 quencher," ...
... Studies show that up to 30% of coffees ordered as ,decaf, ... ... Ever wonder whether the,coffee you had after dinner was really decaf? ... caffeine test strip from,Silver Lake Research, the leader in at-home water quality ...
... today that Gemstone Acquisition Corporation, a wholly-owned,subsidiary of ... purchase all,outstanding shares of common stock of Genelabs ... interest and less any required withholding,taxes. The tender ... announced,Agreement and Plan of Merger dated October 29, ...
Cached Biology Technology:LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates 2Is Your Decaf Really Decaf? 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... A new study compares the relative rate of molecular evolution ... wanted to know whether evolution marches on at a steady pace ... of individual letters of the genetic code occur more rapidly ... study appears in the Proceedings of the Royal Society B ...
... Ga. - A well-documented suppressor of immunity that,s used ... to change its spots, researchers report. In the ... 2,3-dioxegenase, or IDO, also appears capable of helping key ... the invader, said Dr. Tracy L. McGaha, immunologist at ...
... 7, 2014   Dynasil Corporation of America ("Dynasil" ... developer of sensing, detection and analysis technology for homeland ... has regained compliance with the $1.00 minimum bid price ... As previously announced, on March 26, 2013, ...
Cached Biology News:Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3Finding about classic suppressor of immunity points toward new therapies for bad infections 2Finding about classic suppressor of immunity points toward new therapies for bad infections 3Dynasil Regains Compliance with NASDAQ Listing Requirements 2
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
... acetylcholinesterase (AChE) activity. This is a highly ... non-radioactive and easy to use assay for ... acetylcholine. A series of coupled enzyme reactions ... a change in luminescence. Inhibitors of AChE ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: